Skip to main content Accessibility help
  • Print publication year: 2010
  • Online publication date: December 2010

112 - Hydromorphone extended-release

from Section 12 - New and Emerging Analgesics


1. BarashPG, ed. Clinical Anesthesia, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2005, pp. 465–497.
2. WeinsteinSM. A new extended release formulation (OROS®) of hydromorphone in the management of pain. Ther Clin Risk Manage 2009:5 75–80.
3.Palladone medication guide.
4. DroverDR, AngstMS, ValleM, RamaswamyB, NaiduS, StanskiDR, VerottaD. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 2002;97(4):827–36.
5. AngstMS, DroverDR, LotschJ, et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 2001;94(1):63–73.
6.FDA alert: Alcohol-Palladone™ Interaction;
7. WaldenM, NichollsFA, SmithKJ. The effect of ethanol on the release of opioids from oral prolonged-release preparations. Drug Dev Industr Pharm 2007;33:1101–1111.
8. VashiV, HarrisS, El-TahtawyA, WuD, CiprianoA. Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules. J Clin Pharmacol 2005;45(5):547–554.
9. PalangioM, NorthfeltDW, PortenoyRK, BrookoffD, DoyleRT Jr, DornseifBE, DamaskMC. Dose conversion and titration with a novel, once daily, OROS osmotic technology, extended-release formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002;23(5):355–368.
10. SathyanG, XuE, ThipphawongJ, GuptaSK. Pharmacokinetic profile of a 24-hour controlled-release OROS® formulation of hydromorphone in the presence and absence of food. BMC Clin Pharmacol 2007;7:2.
11. SathyanG, SivakumarK, ThipphawongJ. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin 2008;24(1):297–305.